CV Sciences Strengthens Balance Sheet Through Strategic Debt Conversion

CV Sciences converts debt to equity to improve cash flow and expands into sports nutrition with its new +PlusHLTH brand, aiming for growth in 2026.

CV Sciences, a wellness company specializing in plant-based products, has announced a significant financial restructuring aimed at fueling its future growth. Confirmed on March 10, 2026, the move is centered on converting outstanding convertible notes into common stock, a step CEO Joseph Dowling has characterized as a transformative milestone for the business.

Financial Metrics and Shareholder Considerations

The conversion has been set at a price of $0.06 per share, which stands above the stock's recent trading level of approximately $0.0456. A primary objective of this restructuring is to eliminate the company's monthly cash repayment obligations, thereby providing immediate relief to its cash flow.

This financial maneuver increases the total principal amount of certain notes by 20% to around $2.26 million. In theory, this could lead to the issuance of up to 37.6 million new shares. To protect existing shareholder interests, initial investor ownership is capped at 4.99%, with a potential optional increase to 9.99%. Market observers see the debt reduction as a necessary step for CV Sciences to maintain operational agility within the highly competitive wellness sector, freeing up capital for direct investment in product development and market expansion.

A Shift Toward Portfolio Diversification

Alongside its financial repositioning, CV Sciences is actively broadening its product lineup beyond its historical focus on hemp extracts. The company is venturing into the sports nutrition segment with the launch of "Empowr," a plant-based protein and creatine formula marketed under its +PlusHLTH brand.

The company's core business remains stable despite this new direction. According to SPINS market data, the +PlusCBD brand continues to hold its position as one of the top-selling hemp products in the U.S. natural products retail channel. Manufacturing facilities in San Diego, Grand Junction, and Warsaw support both its proprietary brands and contract manufacturing operations.

Path to Improved Financial Health

The company's financial performance shows signs of stabilization. For the full year 2025, CV Sciences reported a positive adjusted EBITDA for the first time since 2019. While third-quarter 2025 revenue declined year-over-year to $3.3 million, the gross margin remained solid at 48.5%.

A key priority for the 2026 fiscal year is the successful integration of new product lines from its Cultured Foods and Elevated Softgels subsidiaries. With a streamlined balance sheet, management is now focused on scaling the +PlusHLTH brand and defending its market leadership in the natural hemp products sector.